Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors

Blockade of programmed cell death ligand‐1 with durvalumab has shown efficacy and safety in large, international studies of patients with advanced solid tumors. A phase 1, non‐randomized, open‐label multicenter study was initiated to evaluate durvalumab in a Japanese population. The first part of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Iguchi, Haruo, Yamamoto, Noboru, Hayama, Manabu, Nii, Masahiro, Ueda, Shinya, Komuro, Keiko, Sugimoto, Mariko, Vlahovic, Gordana, Kozuki, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501043/
https://www.ncbi.nlm.nih.gov/pubmed/30891877
http://dx.doi.org/10.1111/cas.14003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501043/
https://www.ncbi.nlm.nih.gov/pubmed/30891877
http://dx.doi.org/10.1111/cas.14003

Ejemplares similares